Novartis AG filings document the Swiss pharmaceutical issuer’s financial results, annual reporting, R&D updates, capital structure and material events. As a foreign private issuer, Novartis furnishes Form 6-K reports that include quarterly and annual financial reports, condensed financial statements, nonfinancial reporting, product and pipeline disclosures, and regulatory developments for priority brands and clinical programs.
The filing record also covers financing activity through Novartis Capital Corporation, including terms agreements, guaranteed debt securities, officer certificates and legal opinions incorporated into registration statements. Other recurring disclosure areas include Form 20-F annual-report status, governance matters, shareholder voting matters, material agreements, operating results, risk factors and clinical or regulatory disclosures tied to the company’s global medicines portfolio.
Novartis Capital Corporation launched a preliminary prospectus supplement under its shelf registration to offer senior unsecured notes across multiple tranches, including a floating‑rate series using Compounded SOFR and fixed‑rate series maturing from 2028 to 2055. The notes will be fully and unconditionally guaranteed by Novartis AG and issued in book‑entry form through DTC, with access via Clearstream and Euroclear. There is no sinking fund.
Novartis may redeem the fixed‑rate notes at its option as described, and both the fixed and floating tranches may be redeemed for certain tax reasons. The notes will not be listed, and an active trading market may not develop. Key risks noted include potential price volatility with interest rates and credit ratings, structural subordination to subsidiary liabilities, effective subordination to any future secured debt, and SOFR‑related benchmark risks for the floating‑rate tranche. Net proceeds will be used for general corporate purposes outside Switzerland, including refinancing existing indebtedness.
Novartis AG filed an initial beneficial ownership report (Form 3) for Tourmaline Bio, Inc. (TRML). The filing lists 24,030,382 shares of common stock beneficially owned on an indirect basis, with the shares held by Torino Merger Sub Inc., an indirect wholly owned subsidiary. The event date is 10/28/2025. No derivative securities were reported.
Novartis AG agreed to acquire Avidity Biosciences for USD 72.00 per share in cash, valuing Avidity at approximately USD 12bn on a fully diluted basis and implying an enterprise value of about USD 11bn. The deal, unanimously approved by both boards, is expected to close in H1 2026, subject to completion of a SpinCo separation, regulatory approvals and Avidity stockholder approval.
The transaction adds three late-stage programs in neuromuscular diseases—DM1, FSHD and DMD—and Avidity’s muscle-directed AOC platform to Novartis’ neuroscience pipeline. Novartis states the acquisition raises its expected 2024–2029 sales CAGR from +5% to +6% and targets planned product launches before 2030. Prior to closing, Avidity will separate its early-stage precision cardiology programs into “SpinCo.” Avidity stockholders will receive one SpinCo share for every ten Avidity shares and/or a pro rata cash distribution if SpinCo or its assets are sold before closing.
The purchase price reflects a 46% premium to Avidity’s October 24, 2025 closing price. Until completion, both companies will operate independently.
Novartis announced FDA approval of Rhapsido (regibrutinib) as the first oral Brutons tyrosine kinase inhibitor (BTKi) for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Rhapsido is taken twice daily, requires no injections or laboratory monitoring, and demonstrated onset of well-controlled disease (UAS7 ) as early as Week 2 and at Week 12, with about one-third of patients achieving complete absence of itch and hives at Week 12.
The prescribing information reports a safety profile that does not require lab monitoring; the most common adverse events (>=3%) were nasal congestion, nasopharyngitis, bleeding, headache, nausea, and abdominal pain. Novartis notes remibrutinib is also in development for chronic inducible urticaria, food allergy, and hidradenitis suppurativa.
Novartis announced positive top-line results from two global Phase III trials (NEPTUNUS-1 and NEPTUNUS-2) of ianalumab in adults with active Sjögren's disease. Both trials met the primary endpoint, demonstrating statistically significant improvements in systemic disease activity measured by reduction in ESSDAI versus placebo.
NEPTUNUS-1 enrolled 275 patients and NEPTUNUS-2 enrolled 504, evaluating ianalumab 300 mg subcutaneous monthly or every three months versus placebo for up to 52 weeks. Novartis reported ianalumab was well tolerated with a favorable safety profile, described the medicine as having dual B cell-directed activity, and said it plans to present the data and submit to health authorities globally. The program has FDA Fast Track designation, and the release notes there is no guarantee of approval or commercial success.